1. Home
  2. NTRA

NTRA

Natera Inc.

Logo Natera Inc.

Health Care

Medical Specialities

Nasdaq

as 04-19-2024 4:00pm EST

$
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

Founded: 2003 Country:
United States
United States
Employees: N/A City: AUSTIN
Market Cap: 10.9B IPO Year: 2015
Target Price: $87.57 AVG Volume (30 days): 1.4M
Analyst Decision: Strong Buy Number of Analysts: 15
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -3.78 EPS Growth: N/A
52 Week Low/High: $36.90 - $98.82 Next Earning Date: 05-07-2024
Revenue: $1,082,571,000 Revenue Growth: 31.99%
Revenue Growth (this year): 26.27% Revenue Growth (next year): 17.70%

Share on Social Networks: